|
Population
|
Age range
| |
|
Diagnostic modality for hydrocephalus/CSF hypertension
| |
|
Diagnostic modality for underlying aetiology
| |
|
CD4+ cell count range (for each underlying aetiology)
| |
|
Country population derived from
| |
|
Severity of disease at baseline (using GCS, palur grade, MRC scale, GOS or mRS) for each underlying aetiology
| |
|
Communicating or non-communicating hydrocephalus
| |
|
Intervention
|
Primary VPS or following EVD
| |
|
Catheter type (plain silicon, antibiotic impregnated, silver impregnated)
| |
|
Comparison intervention
|
Description of intervention
| |
|
Frequency of intervention
| |
|
Outcome (for each underlying aetiology and intervention)
|
Survival at 1, 6 and 12 months
| |
|
Causes of death at 1, 6 and 12 months
| |
|
Rate of shunt failure at 1, 6 and 12 months
| |
|
Rates of complication at 1, 6 and 12 months
| |
|
Validated outcome measure at 1, 6 and 12 months
| |
